Bio-Rad Q4 revenue slightly beats estimates, helped by growth in Clinical Diagnostics unit

Bio-Rad Laboratories

12/02/2026 21:25

Overview

Life science research firm's Q4 revenue grew 3.9%, slightly beating analyst expectations

Clinical Diagnostics segment drove Q4 revenue growth, offsetting Life Science segment decline

Company successfully integrated Stilla Technologies, enhancing ddPCR product portfolio

Outlook

Bio-Rad expects 2026 non-GAAP revenue growth of 0.5% to 1.5%

Company estimates 2026 non-GAAP operating margin at 12.0% to 12.5%

Bio-Rad cites geopolitical uncertainty affecting future performance

Result Drivers

CLINICAL DIAGNOSTICS GROWTH - Clinical Diagnostics segment sales increased 8.4%, driven by quality controls, blood typing, and diabetes products

LIFE SCIENCE DECLINE - Life Science segment sales decreased 2.6% due to constrained academic research and biotech funding

STILLA TECHNOLOGIES INTEGRATION - Successful integration of Stilla Technologies expanded ddPCR product portfolio

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
Slight Beat*
$693.20 mln
$688.76 mln (4 Analysts)
Q4 EPS
$26.65
Q4 Net Income
$720 mln
Q4 Gross Margin
49.80%


*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Bio Rad Laboratories Inc is $350.00, about 19.2% above its February 11 closing price of $293.69

The stock recently traded at 29 times the next 12-month earnings vs. a P/E of 31 three months ago

Press Release: ID:nBw3s35LZa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)